Dopamine transporter transmembrane domain polar mutants: δG and δδG values implicate regions important for transporter functions

Molecular Pharmacology

Volumn 57, Issue 6, 2000, Pages 1093-1103

  Itokawa, Masanari ^a   Lin, Zhicheng ^a   Cai, Ning Sheng ^a   Wu, Cindy ^a   Kitayama, Shigeo ^a,b   Wang, Jia Bei ^a,c   Uhl, George R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL STRAIN COS1; CONTROLLED STUDY; DOPAMINE UPTAKE; MOLECULAR RECOGNITION; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; THERMODYNAMICS;

ALANINE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; COCAINE; COS CELLS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR SEQUENCE DATA; MUTATION; NERVE TISSUE PROTEINS; PROTEIN CONFORMATION; RATS; TRANSFECTION; TRITIUM;

EID: 0034094557     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J Biol Chem 272:4245-4251.
2. Bergman J, Madras BK, Johnson SE and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251:150-155.
3. Boja JW, Vaughan RA, Patel A, Shaya E and Kuhar MJ (1944) Dopamine Receptors and Transporters: Pharmacology, Structure and Function. New York, Marcel Dekker.
4. Chen JG, Liu-Chen S and Rudnick G (1997) External cysteine residues in the serotonin transporter. Biochemistry 36:1479-1486.
5. Clackson T, Ultsch MH, Wells JA and de Vos AM (1998) Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol 277:1111-1128.
6. Cunningham BC and Wells JA (1993) Comparison of a structural and a functional epitope. J Mol Biol 234:554-563.
7. Edvardsen O and Dahl SG (1994) A putative model of the dopamine transporter. Brain Res Mol Brain Res 27:265-274.
8. Farrens DL, Altenbach C, Yang K, Hubbell WL and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
9. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H and Kobilka BK (1997) Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J 16:6737-6747.
10. Han M, Smith SO and Sakmar TP (1998) Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 37:8253-8261.
11. Himanen JP, Mirza UA, Chait BT, Bookchin RM and Manning JM (1996) A recombinant sickle hemoglobin triple mutant with independent inhibitory effects on polymerization. J Biol Chem 271:25152-25156.
12. Kitayama S, Shimada S and Uhl GR (1992a) Parkinsonism-inducing neurotoxin MPP : Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neural 32:109-111.
13. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM and Uhl GR (1992b) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 89:7782-7785.
14. Lin Z, Wang W, Kopajtic T, Revay RS and Uhl GR (1999) Dopamine transporter: Transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol Pharmacol 56:434-447.
15. + and voltage dependence of the transporter. J Biol Chem 273:29341-29351.
16. Marie J, Koch C, Pruneau D, Paquet JL, Groblewski T, Larguier R, Lombard C, Deslauriers B, Maigret B and Bonnafous JC (1999) Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mo Pharmacol 56:92-101.
17. Merickel A, Kaback HR and Edwards RH (1997) Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J Biol Chem 272:5403-5408.
18. Moro S, Hoffmann C and Jacobson KA (1999) Role of the extracellular loops of G protein-coupled receptors in ligand recognition: A molecular modeling study of the human P2Y1 receptor. Biochemistry 38:3498-3507.
19. Nguyen BD, Zhao X, Vyas K, La Mar GN, Lile RA, Brucker EA, Phillips GN Jr, Olson JS and Wittenberg JB (1998) Solution and crystal structures of a sperm whale myoglobin triple mutant that mimics the sulfide-binding hemoglobin from Lucina pectinata. J Biol Chem 273:9517-9526.
20. Norregaard L, Frederiksen D, Nielsen EO and Gether U (1998) Delineation of an endogenous zinc-binding site in the human dopamine transporter. EMBO J 17: 4266-4273.
21. Paas Y, Eisenstein M, Medevielle F, Teichberg VI and Devillers-Thiery A (1996) Identification of the amino acid subsets accounting for the ligand binding specificity of a glutamate receptor. Neuron 17:979-990.
22. Paterlini G, Portoghese PS and Ferguson DM (1997) Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor: A model for receptor activation. J Med Chem 40:3254-3262.
23. Penado KM, Rudnick G and Stephan MM (1998) Critical amino acid residues in transmembrane span 7 of the serotonin transporter identified by random mutagenesis. J Biol Chem 273:28098-28106.
24. Pifl C, Giros B and Caron MG (1993) Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13:4246-4253.
25. Raman D, Osawa S and Weiss ER (1999) Binding of arrestin to cytoplasmic loop mutants of bovine rhodopsin. Biochemistry 38:5117-5123.
26. Ritz MC, Lamb RJ, Goldberg SR and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
27. Romero A, De la Cerda B, Varela PF, Navarro JA, Hervas M and De la Rosa MA (1998) The 2.15 Å crystal structure of a triple mutant plastocyanin from the cyanobacterium Synechocystis sp. PCC 6803. J Mol Biol 275:327-336.
28. Schreiber G and Fersht AR (1995) Energetics of protein-protein interactions: Analysis of the barnase-barstar interface by single mutations and double mutant cycles. J Mol Biol 248:478-486.
29. Self DW and Nestler EJ (1995) Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18:463-495.
30. Serrano L, Horovitz A, Avron B, Bycroft M and Fersht AR (1990) Estimating the contribution of engineered surface electrostatic interactions to protein stability by using double-mutant cycles. Biochemistry 29:9343-9352.
31. Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M and Uhl G (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science (Wash DC) 254:576-578.
32. Spain JW and Coscia CJ (1987) Multiple interconvertible affinity states for the delta opioid agonist-receptor complex. J Biol Chem 262:8948-8951.
33. Sullivan FX, Sobolov SB, Bradley M and Walsh CT (1991) Mutational analysis of parasite trypanothione reductase: Acquisition of glutathione reductase activity in a triple mutant. Biochemistry 30:2761-2767.
34. Uze G, Di Marco S, Mouchel-Vielh E, Monneron D, Bandu MT, Horisberger MA, Dorques A, Lutfalla G and Mogensen KE (1994) Domains of interaction between alpha interferon and its receptor components. J Mol Biol 243:245-257.
35. Vishnivetskiy SA, Paz CL, Schubert C, Hirsch JA, Sigler PB and Gurevich VV (1999) How does arrestin respond to the phosphorylated state of rhodopsin? J Biol Chem, 274:11451-11454.
36. Wells JA (1991) Systematic mutational analyses of protein-protein interfaces. Methods Enzymol 202:390-411.
37. Williams KA (2000). Three-dimensional structure of the ion-coupled transport protein NhaA. Nature (Lond) 403:112-115.
38. Witkin JM (1994) Pharmacotherapy of cocaine abuse: Preclinical development. Neurosci Biobehav Rev 18:121-142.
39. Woolverton WL and Johnson KM (1992) Neurobiology of cocaine abuse. Trends Pharmacol Sci 13:193-200.